Three Pricing Models That Address the High-Cost Gene, Cell Therapies
Three Pricing Models That Address the High-Cost Gene, Cell TherapiesHere are three innovative structures in pricing models to address the high-cost of curative therapies.
Gene Therapy Advances: What Health Execs Should KnowGene therapy is leaving its mark, while payers contemplate payment models, value, and efficacy issues.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic LeukemiaA new era of treatment has arrived—here’s what you need to know.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.